Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: biosimilars

ACR-Led Resolutions Supporting Research Funding, Biosimilars Access Advance at Annual AMA House of Delegates Meeting

From the College  |  June 23, 2025

An ACR-led resolution that calls for the protection of NIH funding and the ability to negotiate indirect costs will become AMA policy, along with several other resolutions supported by the ACR.

Filed under:American College of RheumatologyLegislation & Advocacy Tagged with:ACR advocacyAMA House of Delegates (HOD)

Underwater Biosimilars Coalition Shares Results of Practice Survey with Congressional Leaders

From the College  |  May 16, 2025

This week, the Coalition sent Congressional leadership a letter detailing the results of a recent survey about how underwater biosimilars are impacting physicians’ ability to provide high-quality care. Almost all of the nearly 200 practices queried reported being  underwater on several biosimilars, with rituximab and infliximab biosimilars being the most common.

Filed under:InsuranceLegislation & AdvocacyPractice Support Tagged with:ACR advocacyBiosimilars

Colin Edgerton, MD, Testifies in Congressional Hearing on Biosimilars

Vanessa Caceres  |  April 21, 2025

In front of the U.S. House Ways and Means Subcommittee, Dr. Edgerton described how challenges of biosimilar costs threaten patient care and outlined several potential legislative solutions.

Filed under:InsuranceLegislation & Advocacy Tagged with:BiosimilarsWays and Means Committee

Reproductive Health, Biosimilars & More in Focus at SOTA 2025

Ruth Jessen Hickman, MD  |  January 30, 2025

Reproductive health, biosimilars, IgG4-related disease and much more—five speakers give us a sneak peek into important topics being addressed at the ACR’s 2025 State-of-the-Art Clinical Symposium, April 4–6.

Filed under:Biologics/DMARDsConditionsEducation & TrainingGuidanceMeeting ReportsOther ACR meetings Tagged with:ACR State-of-the-Art Clinical SymposiumBiosimilarsIgG4 related diseaseLupusOsteoporosispregnancypregnancy complicationspregnant womenskinState-of-the-Art Clinical Symposium

After Coalition Meeting, CMS Leadership Agrees to Closer Look at Underwater Biosimilars

From the College  |  October 21, 2024

The Underwater Biosimilars Coalition shared with the Centers for Medicare & Medicaid Services concerns about problems arising from the average sales price payment methodology and discussed potential options for addressing these challenges.

Filed under:Billing/CodingLegislation & AdvocacyPractice Support Tagged with:ACR advocacyBiosimilarsCoalition of State Rheumatology Organizations (CSRO)

ACR-Led Coalition Working Toward Legislative Solutions for Underwater Biosimilars

From the College  |  September 21, 2024

The Underwater Biosimilars Coalition will meet with the Medicare Payment Advisory Commission to discuss concerns about inadequate reimbursement for certain biosimilars, which has limited beneficiary access to these lower-cost alternative therapies.

Filed under:Billing/CodingLegislation & AdvocacyPractice Support Tagged with:BiosimilarsMedicare reimbursement rate

ACR-Led Coalition on Underwater Biosimilars Grows, Charts Next Steps

From the College  |  August 5, 2024

New members include rheumatology state societies, specialty partners in gastroenterology and patient-facing organizations representing digestive and inflammatory diseases. The ACR and coalition partners are strategizing additional steps to ensure practices receive adequate reimbursement for biosimilars.

Filed under:Billing/CodingLegislation & Advocacy Tagged with:ACR advocacyBiosimilarsReimbursement

The ACR to the CMS: What You Need to Know About Biosimilars and G2211

From the College  |  June 10, 2024

On May 23, Drs. Chris Phillips and Rebecca Shepherd, chairs of the ACR’s Committee on Rheumatologic Care and Insurance Subcommittee, respectively, and members of the ACR’s advocacy staff team met with officials from the Centers for Medicare & Medicaid Services to discuss concerns on underwater biosimilars and restrictions on billing G2211.

Filed under:Uncategorized

Commercial Payers Update Reimbursement for Underwater Infliximab Biosimilars

From the College  |  May 5, 2024

Three commercial health insurance payers have increased reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.

Filed under:InsuranceLegislation & Advocacy Tagged with:ACR advocacyBiosimilarsinfliximab

Biosimilars to Denosumab Approved with an Interchangeable Designation

Michele B. Kaufman, PharmD, BCGP  |  April 18, 2024

The FDA has approved the first interchangeable biosimilars for denosumab.

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabdenosumab-bbdzJubbontiProliaWyostXgeva

  • 1
  • 2
  • 3
  • …
  • 31
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences